| |
BMS052 HCV-NS5A Monotherapy in Phase 3 Now
|
| |
| |
DACLATASVIR (BMS-790052), AN NS5A REPLICATION ... - NATAP
www.natap.org/2012/APASL/APASL_19.htm
DACLATASVIR (BMS-790052), AN NS5A REPLICATION COMPLEX INHIBITOR, COMBINED WITH PEGINTERFERON-ALFA-2a AND RIBAVIRIN IN
Quadruple Therapy With BMS-790052, BMS-650032 and Peg-IFN ...
www.natap.org/2011/EASL/EASL_28.htm
Apr 2, 2011 - HCV Cured With out Peginterferon/ribavirin with 2 oral HCV drugs BMS790052+BMS650032: Quadruple Therapy With BMS-790052, ...
Dual therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b-infected null responders - (01/13/12)
BMS-790052, a First-in-Class Potent Hepatitis C Virus NS5A - NATAP
www.natap.org/2010/AASLD/AASLD_58.htm
Nov 3, 2010 - BMS-790052 is a first-in-class and potent NS5A inhibitor with broad ... double-blind, placebo-controlled, MAD monotherapy study were to .
|
|
| |
| |
|
|
|
